Kura Oncology Finance Executive Sells 4,607 Shares

Kura Oncology, Inc. SVP, Finance & Accounting Thomas James Doyle sold 4,607 shares of common stock on September 28, 2026, at $10.4972 per share in a tax sell-to-cover tied to vesting of 1/6th of the underlying performance-based restricted stock units.

Rhea-AI Filing Summary

Kura Oncology, Inc. SVP, Finance & Accounting Thomas James Doyle sold 4,607 shares of common stock on September 28, 2026, at $10.4972 per share in a tax sell-to-cover tied to vesting of 1/6th of the underlying performance-based restricted stock units. After the sale, he directly held 142,428 shares; a separate indirect holding lists 500 shares through his spouse’s 401(k). The direct post-transaction total includes 1,868 shares acquired on May 17, 2026, under the Employee Stock Purchase Plan. No Rule 10b5-1 plan is reported.

Insider Trade Summary

Net Seller: 4,607 shares

Net Sell 2 txns

Insider DOYLE THOMAS JAMES

Role SVP, Finance & Accounting

Sold 4,607 shs ($48K)

Type	Security	Shares	Price	Value
Sale	Common Stock F1, F2	4,607	$10.4972	$48K
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 142,428 shares (Direct); Common Stock — 500 shares (Indirect, spouse's 401(k))

Footnotes (2)

1. F1. Sell-to-cover for taxes associated with the vesting of 1/6th of the underlying shares of performance-based restricted stock units ("PSUs") granted to the Reporting Person on May 31, 2023. Each PSU represents the contingent right to receive one share of the Issuer's common stock based on the achievement of each of three specified development milestones, and the one-year anniversary of each milestone achievement, subject to the Reporting Person's continuous service on each corresponding vesting date. The one-year anniversary of the specified development milestone was determined to be met on September 27, 2026, resulting in the vesting of 1/6th of the underlying shares.
2. F2. Includes 1,868 shares acquired on May 17, 2026 pursuant to the Issuer's Employee Stock Purchase Plan.

Key Figures

Common shares sold: 4,607 shares Sale price per share: $10.4972 per share Direct shares following transaction: 142,428 shares +3 more

6 metrics

Common shares sold 4,607 shares September 28, 2026

Sale price per share $10.4972 per share September 28, 2026

Direct shares following transaction 142,428 shares Reported after the September 28, 2026 transaction

Indirect shares held 500 shares Held through spouse’s 401(k)

Shares included from Employee Stock Purchase Plan 1,868 shares Acquired on May 17, 2026

Underlying shares vesting 1/6th Performance-based restricted stock units

Key Terms

sell-to-cover, performance-based restricted stock units, Employee Stock Purchase Plan

3 terms

sell-to-cover financial

"Sell-to-cover for taxes associated with the vesting"

Sell-to-cover is when part of newly issued or exercised company stock is immediately sold to pay required taxes and fees, so the recipient keeps the remaining shares. For investors this matters because it reduces the number of shares insiders or employees actually hold after a grant, can create small, routine share sales that aren’t signal of cashing out, and slightly increases share supply on the market—like selling a portion of a paycheck to cover the tax bill.

performance-based restricted stock units financial

"underlying shares of performance-based restricted stock units"

Performance-based restricted stock units are a type of employee equity award that converts into company shares only if predefined financial or operational targets are met over a set period. Think of it like a bonus check that becomes stock only when specific goals are hit; it ties pay to results, aligning managers’ incentives with shareholders. Investors care because these awards affect future share count, executive incentives, and signal how management’s success will be measured and rewarded.

Employee Stock Purchase Plan financial

"acquired ... pursuant to the Issuer's Employee Stock Purchase Plan"

An employee stock purchase plan is a company program that lets workers buy shares through small payroll deductions, often at a discount to the market price and after a set offering period. Think of it like a workplace savings plan that turns into ownership: it encourages employees to share in the company’s success and can create predictable buying or selling of stock that investors watch because it affects supply, demand and employee incentives.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many KURA shares did Thomas James Doyle sell, and at what price?

Thomas James Doyle sold 4,607 shares at $10.4972 per share on September 28, 2026. The sale was a sell-to-cover for taxes associated with vesting of performance-based restricted stock units.

What triggered the KURA performance-based stock unit vesting?

The one-year anniversary of a specified development milestone was determined to have been met on September 27, 2026, resulting in vesting of 1/6th of the underlying shares. Vesting was subject to continued service on the corresponding vesting date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/29/2026 - 06:30 PM Accepted by SEC EDGAR 09/29/2026 - 06:30 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

DOYLE THOMAS JAMES

(Last) (First) (Middle)

C/O KURA ONCOLOGY, INC.

4930 DIRECTORS PLACE, SUITE 500

(Street)

SAN DIEGO CALIFORNIA 92121

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Kura Oncology, Inc. [ KURA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, Finance & Accounting

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/28/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/28/2026		S(1)		4,607	D	$10.4972	142,428(2)	D
Common Stock								500	I	spouse's 401(k)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Sell-to-cover for taxes associated with the vesting of 1/6th of the underlying shares of performance-based restricted stock units ("PSUs") granted to the Reporting Person on May 31, 2023. Each PSU represents the contingent right to receive one share of the Issuer's common stock based on the achievement of each of three specified development milestones, and the one-year anniversary of each milestone achievement, subject to the Reporting Person's continuous service on each corresponding vesting date. The one-year anniversary of the specified development milestone was determined to be met on September 27, 2026, resulting in the vesting of 1/6th of the underlying shares.

2. Includes 1,868 shares acquired on May 17, 2026 pursuant to the Issuer's Employee Stock Purchase Plan.

	Teresa Bair, Attorney-in-fact for Thomas Doyle	09/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)